The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Growth I. L.P. M33 sold 76,324 shares of the business’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $232,788.20. Following the sale, the director now directly owns 1,272,724 shares of the company’s stock, valued at approximately $3,881,808.20. This represents a 5.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oncology Institute Stock Performance

Shares of TOI traded down $0.18 during trading hours on Monday, reaching $2.60. 1,946,906 shares of the company’s stock traded hands, compared to its average volume of 998,460. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $3.50. The business’s fifty day simple moving average is $2.52 and its two-hundred day simple moving average is $1.27. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The firm has a market capitalization of $232.01 million, a price-to-earnings ratio of -3.33 and a beta of 0.13.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $104.41 million during the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.

Analysts Set New Price Targets

Separately, BTIG Research began coverage on Oncology Institute in a research report on Thursday, May 15th. They set a “buy” rating and a $7.00 price objective for the company.

Institutional Trading of Oncology Institute

A number of large investors have recently added to or reduced their stakes in TOI. Renaissance Technologies LLC increased its holdings in shares of Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock valued at $56,000 after buying an additional 12,000 shares in the last quarter. XTX Topco Ltd raised its position in shares of Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock worth $63,000 after purchasing an additional 18,448 shares during the period. Citizens Financial Group Inc. RI purchased a new stake in shares of Oncology Institute during the first quarter valued at $71,000. WealthShield Partners LLC acquired a new position in shares of Oncology Institute in the 1st quarter valued at $80,000. Finally, Jane Street Group LLC increased its stake in Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after purchasing an additional 109,769 shares in the last quarter. 36.86% of the stock is currently owned by institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.